

# Drug Coverage Decision for B.C. PharmaCare

## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

Drug	Drug and Brand Name	Dosage form	Strength
	canagliflozin-metformin (Invokamet®) fixed-dose combination (FDC)	oral tablet	50 mg/500 mg 50 mg/850 mg 50 mg/1,000 mg 150 mg/500 mg 150 mg/850 mg 150 mg/1,000 mg
Manufacturer	Janssen Inc.		
Submission Type	New Submission		
Use Reviewed	type 2 diabetes mellitus (T2DM)		
Common Drug Review (CDR)	If CDR reviewed, include: Yes, CDR recommended: <b>Reimburse</b> . Visit the CDR website for more details: <a href="http://www.cadth.ca/sites/default/files/cdr/complete/SR0480_complete_Invokamet-Aug-29-16.pdf">www.cadth.ca/sites/default/files/cdr/complete/SR0480_complete_Invokamet-Aug-29-16.pdf</a>		
and Provincial Review	<p>In the review of canagliflozin-metformin fixed-dose combination [FDC] (Invokamet®), the Ministry of Health (the Ministry) considered the final reviews completed by the Common Drug Review (CDR) which included clinical and pharmacoeconomic evidence review material and the recommendations from CDEC. The Ministry also received Patient Input Questionnaire responses from two Patient Groups.</p> <p>The Drug Benefit Council (DBC) now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the CDEC recommendation and an internal review only. The DBC screened canagliflozin-metformin FDC (Invokamet®) on May 2, 2016. The DBC advised that because canagliflozin-metformin FDC is similar to canagliflozin used for the treatment of T2DM, the Ministry may accept the CDEC's recommendation for canagliflozin-metformin FDC.</p>		
Drug Coverage Decision	<b>Non-Benefit for canagliflozin-metformin FDC.</b>		
Date	<b>February 18, 2022</b>		
Reason(s)	<p><b>Drug coverage decision is consistent with CDEC recommendation.</b></p> <ul style="list-style-type: none"> <li>CDEC recommended that canagliflozin-metformin FDC be reimbursed for the treatment of T2DM with the condition that the drug plan cost for the canagliflozin-metformin FDC should not exceed the combined cost of canagliflozin and metformin administered separately.</li> <li>Canagliflozin-metformin FDC was superior to placebo and metformin for improving glycated</li> </ul>		

	<p>haemoglobin (HbA1c) and body weight.</p> <ul style="list-style-type: none"> <li>At the submitted list price, the cost for canagliflozin-metformin FDC will exceed the combined cost of canagliflozin and metformin administered separately.</li> <li>The Ministry participated in the pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with the manufacturer which were able to address the concerns identified by the CDEC and DBC with respect to the cost-effectiveness and value for money for canagliflozin.</li> <li>The Ministry participated in the pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with the manufacturer, but the pCPA was not able to meet an agreement with the manufacturer for canagliflozin-metformin FDC tablets.</li> <li>The pCPA was successful in reaching an agreement for canagliflozin (Invokana®). However, the manufacturer withdrew from a Product Listing Agreement with BC for canagliflozin.</li> <li>On <b>February 18, 2022</b>, the Ministry will not provide coverage for canagliflozin based on the manufacturer's decision to withdraw and will not provide coverage for canagliflozin-metformin FDC as the pCPA negotiations were unsuccessful.</li> </ul>
Other Information	None

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.